2843 E. Grand River Avenue – #230 East Lansing, MI 48823annie@nlmsf.org 303-783-0924
Reaching For the Cure Together
Medical Articles
MARCH 2017-POTENTIALLY PREVENTABLE EMERGENCY DEPARTMENT VISITS ARE COMMON
Detailed Description: A significant portion of emergency department (ED) visits by patients undergoing cancer treatment can be preventable, and those possibly preventable visits account for a high percentage of the ED visit costs, according to a new analysis.
Detailed Description: Telomeres are found at the ends of human chromosomes and contain thousands of repeats of repetitive TTAGGG DNA sequences. Telomerase is an enzyme that maintains telomere length in cancer cells by adding TTAGGG repeats onto the telomeric ends to compensate for the normal shortening of telomeres in all dividing cells. A majority of human cancers have very short telomeres, indicating that tumors can arise from genetically abnormal cells with dysfunctional telomeres.
JANUARY 2017-NEW STUDY REVEALS A NEW WAY TO STARVE TUMORS TO DEATH
Detailed Description: For a long time, scientists have tried to stop cancer growth by preventing nutrients from reaching tumor cells in order to starve them. Such attempts have not been as successful because cancer cells are perceptive and rely on other backup routes to continue growth. Scientists are now mapping the secondary routes cancer cells use when nutrients are depleted and identifying drugs that block them.
DECEMBER 2016-RADIATION THERAPY IN THE MANAGEMENT OF SOFT TISSUE SARCOMA: A CLINICIAN’S GUIDE TO TIMING, TECHNIQUES, AND TARGETS
Detailed Description: Radiation therapy is a significant component in the multidisciplinary treatment of soft tissue sarcomas. Click here for more information.
OCTOBER 2016-COMPARISON OF MRI AND PET-CT IN DETECTING THE LOCO-REGIONAL RECURRENCE of SOFT TISSUE SARCOMAS DURING SURVEILLANCE
Detailed Description: A research study featured in the journal of Skeletal Radiology found that magnetic resource imaging (MRI) and PET- CT of areas of interest are both recommended methods to evaluate tumor recurrences after surgical excision of soft tissue sarcomas. Click here for more information.
OCTOBER 2016-BIDEN CHECKS IN ON LIQUID BIOPSIES
Detailed Description: Vice President Joe Biden is receiving people working on the Blood Profiling Atlas Project, one of the cancer moonshot’s major projects. It’s aimed at creating a database of liquid biopsies that could help accelerate research. Click here for more information. Click here for more information.
OCTOBER 2016-LARTRUVO (OLARATUMAB) OFFERS NEW PROMISE FOR PATIENTS WITH SOFT TISSUE SARCOMA
Detailed Description: On October 19, 2016, FDA approved Lartruvo (olaratumab) with doxorubicin treatment for patients with soft tissue sarcoma (STS) who cannot be treated with radiation or surgery and for whom chemotherapy is the appropriate treatment. Click here for more information.
OCTOBER 2016-A PHASE II STUDY of TIVOZANIB IN PATIENTS WITH METASTATIC AND NONRESECTABLE SOFT TISSUE SARCOMAS
Detailed Description: Tivozanib is well tolerated and exhibits anti-tumor activity against metastatic soft tissue sarcomas. Click here for more information.
SEPTEMBER 2016-MANAGING ADULT SOFT TISSUE SARCOMAS AND GASTROINTESTINAL STROMAL TUMOURS
Detailed Description: Sarcomas encompass rare, biologically diverse cancers. Paolo Casali, a leading expert, presents an overview of the latest research on the best way to treat them. Click here for more information.
SEPTEMBER 2016-PROS AND CONS GENETIC TESTING AND CANCER
Detailed Description: Genetic testing allows doctors to use preventive actions to screen and reduce the risk of hereditary cancer. Click here for more information.
JULY 2016-ROUTES TO DIAGNOSIS FOR SUSPECTED SARCOMA: THE IMPACT OF SYMPTOMS AND CLINICAL FINDINGS ON THE DIAGNOSTIC PROCESS
Detailed Description: Sarcoma patients often experience a lag in time before being diagnosed. The primary part of this delay can be attributed to the patient and nearby hospitals. Click here for more information.
JUNE 2016-IMMUNOTHERAPY EFFECTIVE AGAINST SOME TYPES OF SARCOMA
Detailed Description: Researchers at the University of Pittsburgh Caner Institute found that an existing cancer immunotherapy drug is effective in reducing tumor size in some types of sarcomas. Click here for more information.
From ASCO . . .
What do all cancer types have in common?
Cells in cancer have become genetically unstable
Cancerous cells are frequently found in an inflammatory environment
Cancerous cells grow uncontrollably
Cancerous cells can avoid/ignore antigrowth signaling
A self-destruct mechanism in cancerous cells is not functioning properly
Cancerous cells have bypassed a replication limit that is not functioning properly
The metabolic machinery within cancerous cells is not functioning normally
Cancerous cells can evade immune-system surveillance
Cells that are oxygen-deprived within a tumor will signal for a new blood flow
Cancerous cells invade nearby tissues and ultimately enter the bloodstream or lymph system, which allows them to spread and colonize in other parts of the body
NOTE from the Foundation: The above-listed commonalities, plus the difficulty of gene mutations, has made Leiomyosarcoma most difficult to treat using immunotherapy breakthroughs. Oncology researchers, however, are working hard to progress toward this goal.
Annual LMS research funding for promising LMS research projects
Founded by the NLMSF: The Annual International LMS Research Roundtable
Think Tank of the Sarcoma Research Community in support of advancing
LMS-specific precision research initiatives
Continuously bridging partnerships/collaboration with organizations to
increase/strengthen resource assistance support
The National LeioMyoSarcoma Foundation (NLMSF) is a 501(c)(3) Non-Profit Charitable Organization and a member of the GuideStar Exchange.
National LeioMyoSarcoma Foundation – NLMSF
2843 E. Grand River Avenue – #230
East Lansing, MI 48823
Contact Us:
Annie Achee
303-783-0924
annie@nlmsf.org
Sarcoma Coalition – We are here for you.
The Sarcoma Coalition brings together advocacy groups throughout the United States,
to build bridges of collaborative resource advocacy and support and Sarcoma Research
Community alliances.
By working together, the Sarcoma Coalition members extend their advocacy strength
and provide a united presence for patients and their families/caregivers.
Medical Articles
MARCH 2017-POTENTIALLY PREVENTABLE EMERGENCY DEPARTMENT VISITS ARE COMMON
Detailed Description: A significant portion of emergency department (ED) visits by patients undergoing cancer treatment can be preventable, and those possibly preventable visits account for a high percentage of the ED visit costs, according to a new analysis.
http://www.cancernetwork.com/cancer-complications/potentially-preventable-emergency-department-visits-are-common
FEBRUARY 2017-TELOMERS AND CANCER
Detailed Description: Telomeres are found at the ends of human chromosomes and contain thousands of repeats of repetitive TTAGGG DNA sequences. Telomerase is an enzyme that maintains telomere length in cancer cells by adding TTAGGG repeats onto the telomeric ends to compensate for the normal shortening of telomeres in all dividing cells. A majority of human cancers have very short telomeres, indicating that tumors can arise from genetically abnormal cells with dysfunctional telomeres.
http://www.news-medical.net/life-sciences/Telomeres-and-Cancer.aspx
JANUARY 2017-NEW STUDY REVEALS A NEW WAY TO STARVE TUMORS TO DEATH
Detailed Description: For a long time, scientists have tried to stop cancer growth by preventing nutrients from reaching tumor cells in order to starve them. Such attempts have not been as successful because cancer cells are perceptive and rely on other backup routes to continue growth. Scientists are now mapping the secondary routes cancer cells use when nutrients are depleted and identifying drugs that block them.
Read more at : https://medicalxpress.com/news/2017-01-unveils-starve-tumors-death.html#jCp
DECEMBER 2016-RADIATION THERAPY IN THE MANAGEMENT OF SOFT TISSUE SARCOMA: A CLINICIAN’S GUIDE TO TIMING, TECHNIQUES, AND TARGETS
Detailed Description: Radiation therapy is a significant component in the multidisciplinary treatment of soft tissue sarcomas. Click here for more information.
OCTOBER 2016-COMPARISON OF MRI AND PET-CT IN DETECTING THE LOCO-REGIONAL RECURRENCE of SOFT TISSUE SARCOMAS DURING SURVEILLANCE
Detailed Description: A research study featured in the journal of Skeletal Radiology found that magnetic resource imaging (MRI) and PET- CT of areas of interest are both recommended methods to evaluate tumor recurrences after surgical excision of soft tissue sarcomas. Click here for more information.
OCTOBER 2016-BIDEN CHECKS IN ON LIQUID BIOPSIES
OCTOBER 2016-LARTRUVO (OLARATUMAB) OFFERS NEW PROMISE FOR PATIENTS WITH SOFT TISSUE SARCOMA
Detailed Description: On October 19, 2016, FDA approved Lartruvo (olaratumab) with doxorubicin treatment for patients with soft tissue sarcoma (STS) who cannot be treated with radiation or surgery and for whom chemotherapy is the appropriate treatment. Click here for more information.
OCTOBER 2016-A PHASE II STUDY of TIVOZANIB IN PATIENTS WITH METASTATIC AND NONRESECTABLE SOFT TISSUE SARCOMAS
Detailed Description: Tivozanib is well tolerated and exhibits anti-tumor activity against metastatic soft tissue sarcomas. Click here for more information.
SEPTEMBER 2016-MANAGING ADULT SOFT TISSUE SARCOMAS AND GASTROINTESTINAL STROMAL TUMOURS
Detailed Description: Sarcomas encompass rare, biologically diverse cancers. Paolo Casali, a leading expert, presents an overview of the latest research on the best way to treat them. Click here for more information.
SEPTEMBER 2016-PROS AND CONS GENETIC TESTING AND CANCER
Detailed Description: Genetic testing allows doctors to use preventive actions to screen and reduce the risk of hereditary cancer. Click here for more information.
JULY 2016-ROUTES TO DIAGNOSIS FOR SUSPECTED SARCOMA: THE IMPACT OF SYMPTOMS AND CLINICAL FINDINGS ON THE DIAGNOSTIC PROCESS
Detailed Description: Sarcoma patients often experience a lag in time before being diagnosed. The primary part of this delay can be attributed to the patient and nearby hospitals. Click here for more information.
JUNE 2016-IMMUNOTHERAPY EFFECTIVE AGAINST SOME TYPES OF SARCOMA
Detailed Description: Researchers at the University of Pittsburgh Caner Institute found that an existing cancer immunotherapy drug is effective in reducing tumor size in some types of sarcomas. Click here for more information.
From ASCO . . .
NOTE from the Foundation: The above-listed commonalities, plus the difficulty of gene mutations, has made Leiomyosarcoma most difficult to treat using immunotherapy breakthroughs. Oncology researchers, however, are working hard to progress toward this goal.
Below is a link to the article in Cancer World:
http://cancerworld.net/e-grandround/managing-adult-soft-tissue-sarcomas-and-gastrointestinal-stromal-tumours/
Inform – Inspire – Empower
Our Mission is our Passion:
“What we can do today can affect what happens tomorrow”
Think Tank of the Sarcoma Research Community in support of advancing
LMS-specific precision research initiatives
increase/strengthen resource assistance support
The National LeioMyoSarcoma Foundation (NLMSF) is a 501(c)(3) Non-Profit Charitable Organization and a member of the GuideStar Exchange.
National LeioMyoSarcoma Foundation – NLMSF
2843 E. Grand River Avenue – #230
East Lansing, MI 48823
Contact Us:
Annie Achee
303-783-0924
annie@nlmsf.org
Sarcoma Coalition – We are here for you.
The Sarcoma Coalition brings together advocacy groups throughout the United States,
to build bridges of collaborative resource advocacy and support and Sarcoma Research
Community alliances.
By working together, the Sarcoma Coalition members extend their advocacy strength
and provide a united presence for patients and their families/caregivers.
“Achieving More Together!”